Epidemiologist Erin Bowles, MPH, is looking at cancer screening and treatment from many different perspectives. Her research brings new insight into cancer risk factors, diagnosis, treatment, and survivorship, while helping improve cancer care for patients and families.
Erin received an R50 mid-career research award from the National Cancer Institute (NCI). This award is given to cancer researchers who have demonstrated successes and contributions to cancer research as a non-principal investigator. As a key member of 2 large cancer collaborations — the NCI's Breast Cancer Surveillance Consortium and the Health Care Systems Cancer Research Network (CRN) — Erin has developed diverse expertise that includes reading mammograms for breast density and using administrative data to understand patterns of care in cancer treatment.
Her current work includes:
Erin’s experience working with large observational cohorts and collaborations with numerous study teams over the past 20 years has provided her with expertise in data collection and quality control for many subject areas. She is also a manager of the Collaborative Science Division at KPWHRI, providing leadership, supervision, mentorship, and support to junior faculty.
Breast cancer; colorectal cancer; multiple myeloma; thyroid cancer; pancreatic cancer; biostatistics; epidemiology; mammography; mammographic breast density; cancer treatment; cancer screening and surveillance; automated data collection; quality of care; medication use; care coordination; administrative data
Access to care; health disparities; health outcomes research; quality of life; measurement of change in health care systems; practice variation
Menopause; hormone replacement therapy (HRT); breast cancer
Cognitive health and dementia; biostatistics; epidemiology; medication use; cancer
Pharmacoepidemiology; observational study research methods; chemotherapy; radiation exposure
Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL. Longitudinal change in mammographic density among ER-positive breast cancer patients using tamoxifen. Cancer Epidemiol Biomarkers Prev. 2015 Nov 6. pii: cebp.0412.2015. [Epub ahead of print]. PubMed
Chubak J, Bowles EJ, Yu O, Buist DS, Fujii M, Boudreau DM. Breast cancer recurrence in relation in antidepressant use. Cancer Causes Control. 2015 Oct 30. [Epub ahead of print]. PubMed
Gard CC, Aiello Bowles EJ, Miglioretti DL, Taplin SH, Rutter CM. Misclassification of Breast Imaging Reporting And Data System (BI-RADS) mammographic density and implications for breast density reporting legislation. Breast J. 2015 Sep-Oct;21(5):481-9. doi: 10.1111/tbj.12443. Epub 2015 Jul 1. PubMed
Carroll NM, Delate T, Menter A, Hornbrook MC, Kushi L, Aiello Bowles EJ, Loggers ET, Ritzwoller DP. Use of bevacizumab in community settings: toxicity profile and risk of hospitalization in patients with advanced non-small-cell lung cancer. J Oncol Pract. 2015 Sep;11(5):356-62. doi: 10.1200/JOP.2014.002980. Epub 2015 Jun 9. PubMed
Nyante SJ, Sherman ME, Pfeiffer RM, Berrington de Gonzalez A, Brinton LA, Aiello Bowles EJ, Hoover RN, Glass A, Gierach GL. Prognostic significance of mammographic density change after initiation of tamoxifen for ER-positive breast cancer. J Natl Cancer Inst. 2015 Feb 6;107(3). pii: dju425. doi: 10.1093/jnci/dju425. Print 2015. PubMed
Ludman EJ, McCorkle R, Bowles EA, Rutter CM, Chubak J, Tuzzio L, Jones S, Reid RJ, Penfold R, Wagner EH. Do depressed newly diagnosed cancer patients differentially benefit from nurse navigation? Gen Hosp Psychiatry. 2015 Feb 28. pii: S0163-8343(15)00038-9. doi: 10.1016/j.genhosppsych.2015.02.008 [Epub ahead of print]. PubMed
New study will develop risk models to improve clinical guidelines and practice.
Kaiser Permanente Washington has been part of the national Breast Cancer Surveillance Consortium since 1994. Learn about the Kaiser Permanente Washington Breast Cancer Surveillance Registry here.
The division contributes to research across the institute with methodological and subject matter expertise.
How KPWHRI is contributing to better cancer screening and better outcomes for patients.
Cell by cell, scientists are building a high-resolution map of brain changes in Alzheimer’s disease.